This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Literature retrieved using the above keywords and published were included with a time limit from 1st January 2020 to 8th Aug 2024.ResultsThe ResultsThe bibliometric analysis of COVID-19 and Sudden Cardiac Death highlights key research trends from 2020 to 2024, revealing a rapid surge in scientific output during the pandemic.
Objectives This study sought to evaluate the recovery of cardiovascular testing in Asia 1 year into the COVID-19 pandemic. Cardiovascular testing volumes in Asia decreased by 53% from March 2019 to April 2020, then recovered 96% of this decrease by April 2021, compared with 98% recovery in the rest of the world.
Background The COVID-19 pandemic necessitated major reallocation of healthcare services. Our aim was to assess the impact on paediatric congenital heart disease (CHD) procedures during different pandemic periods compared with the prepandemic period, to inform appropriate responses to future major health services disruptions.
The cumulative incidence of MACE and all- cause of mortality in COVID-19 and non-COVID-19 pneumonia groups. The results indicate a lower risk of cardiovascular disease in COVID-19 patients. The results indicate a lower risk of cardiovascular disease in COVID-19 patients.
survival rates from out-of-hospital cardiac arrests fell significantly at the beginning of the COVID-19 pandemic in 2020 and only slightly. This news release contains updated information and data not included in the abstract. Research Highlights: U.S.
Out-of-hospital cardiac arrest survival rates dropped significantly at the onset of the COVID-19 pandemic in 2020 and have continued to remain lower than in the pre-pandemic years of 2015–2019, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.,
The sociodemographic characteristics of patients undergoing intervention for aortic stenosis (AS) in England, and the impact of COVID-19, is unknown. Rates of SAVR declined during COVID-19 for all groups, but TAVI rates increased steadily. Results Of 179 645 procedures, there were 139 990 SAVR (mean age 71±10.8
Background and aim Increased mortality during the COVID-19 pandemic is not explained exclusively by COVID-19 infection and its complications. We analysed non-COVID-19 causes of mortality in a population analysis based on data from the Spanish National Institute of Statistics. compared with 2019.
Background It is unclear how COVID-19 pandemic affected care and outcomes among patients who are diagnosed with ST-elevation myocardial infarction (STEMI) in the USA. reduction in admissions in 2020. reduction in admissions in 2020. In 2020, 3.0% 12.55, P < 0.001) with COVID-19 infection compared with no infection.
When the COVID-19 pandemic arrived in 2020, however, it derailed progress in many locations. Over the past three decades, reductions in death from leading killers fueled this progress, including diarrhea and lower respiratory infections, as well as stroke and ischemic heart disease.
I’m a cardiologist, and the first disconnect that became glaringly obvious very quickly was the impact COVID was having on the heart. As I walked through COVID rooms in the Spring of 2020 trying to hold my breath, I waited for a COVID cardiac tsunami. There never was a cardiac tsunami from COVID.
Background COVID-19 pandemic led to a reduction in hospital admissions and intervention for other diseases in many countries. We aimed to assess the effect of COVID-19 pandemic on cardiovascular disease (CVD) hospitalisations, management and mortality in Switzerland.
BackgroundRecently, the use of telemedicine technology has increased due to the Covid-19 pandemic. This study aimed to identify the applications of telemedicine for cardiovascular diseases management during the Covid-19 pandemic.MethodsThis scoping study was conducted in 2023.
Objective To assess the feasibility, efficacy and safety of performing exercise stress echocardiography (ESE) for the assessment of myocardial ischaemia during the COVID-19 pandemic. Of the 17 healthcare professionals performing ESE, none contracted COVID-19 during this period. SE service performance increased to 96.8%
Objectives (1) To evaluate the prevalence and hospitalisation rate of COVID-19 infections among patients with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) in the Royal Brompton and Harefield Hospital Cardiovascular Research Centre (RBHH CRC) Biobank. (2) of the cardiomyopathy cohort reporting COVID-19 symptoms.
Background Acute myocardial infarction (AMI) is one of the most lethal complications of COVID-19 hospitalization. In this study, we looked for the occurrence of AMI and its effects on hospital outcomes among COVID-19 patients. Methods Data from the 2020 California State Inpatient Database was used retrospectively.
We examined incidental non-COVID-19 cardiovascular pathology in college athletes undergoing postinfection return-to-play screening. Conclusion Major non-COVID-19 cardiovascular pathology was identified in 1/500 college athletes undergoing return-to-play screening.
The World Health Organisation (WHO) formally proclaimed COVID-19, the illness spread by a zoonotic SARS-CoV-2, as a pandemic in March 2020, after it had started to spread in late 2019. And, addressing myocardial infarction, recent studies have shown that 1-4% of Athletes untimely die due to myocarditis caused by COVID-19.
Objective To identify the most common transthoracic echocardiogram (TTE) parameters in patients hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19) and their association with myocardial injury and outcomes. Moreover, COVID-19-induced myocarditis remains extremely rare.
The current pandemic of a new coronavirus infection, which began in March 2020, was marked by an increase in cardiovascular diseases, including an increase in the number of patients with AF. However, most research in this area has focused on hospital patients.
Background We sought to examine a 1-year incidence of atrial fibrillation (AF) among patients with SARS-CoV-2 virus (COVID-19) in comparison to those with non-COVID-19 acute upper respiratory infection (AURI). Similar findings were observed for the COVID-19 (n=169 687) versus AURI prepandemic (n=169 486) comparison (2.7%
Prateek Bhatnagar, Director Cardiac Surgery & Chief Cardiology Surgeon at Care Hospital, Banjara Hills, Hyderabad, has successfully operated & discharged India’s first post Covid19 recovered patient who on 16th July, 2020, underwent a triple bypass surgery under Dr. Bhatnagar & his team of doctors here.
New research confirms what public health leaders have been fearing: The significant uptick in the cardiovascular disease (CVD) death rate that began in 2020 has continued. The findings are reported in the American Journal of Preventive Medicine.
Aims We evaluated the effects of the COVID-19 pandemic on hospital admission and quality of care for acute coronary syndrome. Data were fitted to segmented regression models with March 2020 as the breakpoint. In patients with STEMI, the pandemic did not affect reperfusion rates (0.29%, (95% CI) –1.5%
Background The COVID-19 pandemic disrupted cardiovascular disease management in primary care in England. OpenSAFELY can be used to continuously monitor changes in national quality-of-care schemes to identify changes in key clinical subgroups early and support prioritisation of recovery from care disrupted by COVID-19.
Background:The COVID-19 pandemic has significantly exacerbated sleep problems. Changes in daily life due to COVID-19 were assessed by asking participants to score their current situation compared to their pre-pandemic situation, ranging from 100 (no change) to 0 (complete cessation of daily activities).
Background COVID-19 has caused significant worldwide morbidity and mortality. Objective Ascertain the impact of COVID-19 on people with CHD and define risk factors for adverse outcomes. Methods Multicentre UK study undertaken 1 March 2020–30 June 2021 during the COVID-19 pandemic.
BackgroundPatients with ischemic stroke and concomitant COVID‐19 infection have worse outcomes than those without this infection, but the impact of COVID‐19 on hemorrhagic stroke remains unclear. We aimed to assess if COVID‐19 worsens outcomes in intracerebral hemorrhage (ICH).Methods
Background:COVID-19, primarily a respiratory illness caused by SARS-CoV-2, is associated with vascular complications like ischemia due to endothelial injury, hypercoagulability, and inflammation. Results:Out of 1,171 patients, those who tested positive for COVID-19 had significantly worse outcomes.
Background:Hemorrhagic cerebrovascular manifestations are known to be associated with COVID-19. Comparative outcome analyses between pre-COVID (2016-2019) and COVID year (2020) were performed. Comparative outcome analyses between pre-COVID (2016-2019) and COVID year (2020) were performed.
Background:Different from the negative impact of COVID-19 pandemic on outcomes after out-of-hospital cardiac arrest (OHCA) collapsed before emergency medical service (EMS) arrival, there was a report suggested that COVID-19 pandemic did not affect outcomes after OHCA witnessed by EMS personnel. to 1.07; p = 0.24).
Methods This observational case-control study included consecutive patients whose non-emergency cardiac intervention has been postponed during COVID-19-related lockdown between 19 March and 30 April 2020 (n=193). The planned intervention was deferred by a median of 23 (19–36) days.
The onset of the pandemic and the related public health emergency in early 2020 presented an opportunity for the Network to expand its focus beyond cardiac surgery and help design and execute COVID-19 studies. The performance of the Network has been spectacular,” said Peter K.
BACKGROUND:The association of COVID-19 with higher bleeding risk and worse outcomes in acute ischemic stroke (AIS) undergoing revascularization may be related to the presence of infection symptoms. We compared COVID-negative controls, AS-COVID, and S-COVID using multivariable regression. 2.32], respectively).
Adult patients in 2018 (n=6,051,974) were compared to those in 2020 (n=5,470,813), the first year of the COVID-19 pandemic. To prevent potential confounding by undiagnosed COVID-19, patients in 2019 were not utilized in the analysis. Hospital mortality rate among CVT patients admitted in 2020 was 5%.
Although Australia has been known to offer excellent stroke treatment and care services in recent years (Deloitte Access Economics, 2020), the rise of the COVID‐19 pandemic caused a reduction in resource availability and delays in stroke treatment.
Whether the COVID-19 pandemic impacted stroke etiology is still being investigated, but most studies have been performed outside the United States. Adults (18) with AIS were compared based on admission date: Pre-COVID period (1/1/2019 12/31/2019) vs. COVID period (3/1/2020 3/1/2021).
Background:Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%. but there were fewer women in the COVID-CVST group (50% vs 68%,P<0.01).
IntroductionThe goal of this research project is to investigate the impacts and effects of the COVID‐19 pandemic on acute ischemic stroke treatment in North America. Among patients with an ischemic stroke, thrombectomy administration decreased by up to 25% in February 2020 compared to February 2019 (Zhao et al.,
The outbreak of COVID-19 pandemic was first reported in China between December 2019 and January 2020 and then spread to Europe, with Italy among the first countries with recognized clusters. The COVID-19 pandemic turned everyone’s life upside down and the end of the emergency was declared by WHO only on May 5, 2023.
IntroductionThe coronavirus disease 2019 (COVID‐19) pandemic has had a global impact on healthcare systems. There is limited data on the influence of COVID‐19 on treatment and outcomes in patients with intracranial aneurysms. Of these, 45,979 occurred pre‐COVID and 11,736 during the COVID pandemic period.
Background:Severe COVID-19 infection has been associated with acute respiratory distress syndrome (ARDS) and right ventricular (RV) dysfunction. A retrospective chart review was performed on 41 patients with COVID-19 on ECMO between March and October 2020.
Telehealth visits increased during the COVID-19 pandemic, with a peak in April 2020. About half of primary care visits were telehealth, but the percentage declined and stabilized to about 8% in late 2021.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content